Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2024-12-19 DOI:10.1080/14760584.2024.2441250

Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier

{"title":"Knowledge, attitudes, and perceptions towards pneumococcal vaccines among adults in the United States.","authors":"Salini Mohanty, Jui-Hua Tsai, Ning Ning, Ana Martinez, Rishi P Verma, Bianca Chun, Kelly D Johnson, Nicole Cossrow, M Doyinsola Bailey, Thomas Weiss, Elmira Flem, Jordana K Schmier","doi":"10.1080/14760584.2024.2441250","DOIUrl":null,"url":null,"abstract":"Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"45-52"},"PeriodicalIF":5.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2024.2441250","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: The attitudes and perceptions of healthcare consumers (HCCs) are increasingly becoming more relevant in decision-making with healthcare providers and incorporated into healthcare decision-making by national immunization technical advisory groups and health technology assessment agencies. With newer pneumococcal vaccine options available, HCCs' attitudes and perceptions play a key role in gauging potential acceptance. The objective of this study was to assess HCCs' knowledge, attitudes, and perceptions toward pneumococcal vaccines for adults.

Methods: Between March and May 2024, eligible U.S. adult HCCs were invited to participate in an online survey focusing on experiences and attitudes toward vaccines.

Results: Among 141 participating HCCs, average age was 53.1 years. The majority of participants were male (51.1%) and 64.5% identified as White. Most HCCs received at least one vaccine in the past year (81.6%). HCCs most often received vaccines at medical offices and pharmacies. HCCs supported lowering the age-based pneumococcal vaccine recommendation to all adults 50 years and older and were willing to receive a supplemental pneumococcal vaccine dose following completion of the recommended series for additional protection.

Conclusions: These findings indicate that new adult pneumococcal vaccines would be accepted and valued by HCCs if recommended by HCPs.

查看原文本刊更多论文

美国成年人对肺炎球菌疫苗的了解、态度和看法。

目的：医疗保健消费者 (HCC) 的态度和看法与医疗保健提供者的决策越来越相关，并被国家免疫技术咨询组和卫生技术评估机构纳入医疗保健决策中。随着肺炎球菌疫苗新方案的推出，医护人员的态度和看法在衡量潜在接受度方面起着关键作用。本研究的目的是评估 HCC 对成人肺炎球菌疫苗的认识、态度和看法：方法：在 2024 年 3 月至 5 月期间，邀请符合条件的美国成人 HCC 参与在线调查，重点了解他们对疫苗的经验和态度：在 141 名参与调查的 HCC 中，平均年龄为 53.1 岁。大多数参与者为男性（51.1%），64.5%为白人。大多数 HCC 在过去一年中至少接种过一次疫苗（81.6%）。HCC 最常在医务室和药房接种疫苗。高危人群支持将基于年龄的肺炎球菌疫苗接种建议降低到所有 50 岁及以上的成年人，并愿意在完成建议的系列接种后再接种一剂肺炎球菌疫苗，以获得额外的保护：这些研究结果表明，如果得到保健中心医生的推荐，新的成人肺炎球菌疫苗将得到保健中心医生的接受和重视。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.